Skip to main
HRMY

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 14%
Hold 43%
Sell 14%
Strong Sell 0%

Bulls say

Harmony Biosciences Hldgs is well-positioned for long-term success due to their central nervous system pipeline and WAKIX's potential as a blockbuster drug with expected sales of over $700 million in 2024. The company's therapeutic focus on rare neurological disorders offers significant growth potential, and their strong financials and emphasis on research and development make them an attractive investment opportunity.

Bears say

Harmony Biosciences Hldgs is facing potential challenges in differentiating its product WAKIX in the hypersomnolence market and expanding its indications, with competition from other once-daily neuropsychiatric drugs and potential sales plateau before loss-of-exclusivity. Additionally, its IP legal barriers may not be strong enough to protect against potential generic competition, and future growth may depend on in-licensing new pipeline assets. With limited cash reserves, Harmony Biosciences Hldgs may struggle to sustain profitability and may face risks in demonstrating sufficient safety and efficacy for its current pipeline assets.

HRMY has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 14% recommend Buy, 43% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Buy based on their latest research and market trends.

According to 7 analysts, HRMY has a Buy consensus rating as of Aug 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.